Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | KIF11 | P52732 | 3/20 | 0.46 |
| ▸ | BRAF | P15056 | 3/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.40 |
| ▸ | SELE | P16581 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13429146 | 0.86 | KIF11 (0.48) | MCL1KDM4EKIF11BRAFABCG2 | |
| SCHEMBL13429145 | 0.84 | KIF11 (0.52) | KDM4EKIF11BRAFCYP1A2CYP2C19 | |
| SCHEMBL13429036 | 0.82 | HPGD (0.46) | KDM4EBRAFABCG2CYP1A2CYP2C19 | |
| SCHEMBL2008835 | 0.81 | HPGD (0.54) | KDM4ECYP1A2CYP2C19TNKS2L3MBTL1 | |
| SCHEMBL3225355 | 0.80 | CYP1A2 (0.45) | KDM4EBRAFCYP1A2CYP2C19TNKS2 | |
| SCHEMBL3222448 | 0.80 | CYP1A2 (0.45) | KDM4EBRAFABCG2CYP1A2CYP2C19 | |
| SCHEMBL13429161 | 0.80 | HPGD (0.54) | MCL1KDM4ECYP1A2CYP2C19TNKS2 | |
| SCHEMBL13429074 | 0.80 | ABCG2 (0.51) | KDM4EABCG2CYP1A2CYP2C19TNKS2 | |
| SCHEMBL13429069 | 0.80 | CYP1A2 (0.53) | MCL1KDM4ECYP1A2CYP2C19TNKS2 | |
| SCHEMBL3224936 | 0.80 | MAOB (0.47) | KDM4ECYP1A2CYP2C19TNKS2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | WYETH (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | WYETH (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | MTOR, RICTOR, PIK3CA | MCL1 1036/4885KDM4E 728/4885KIF11 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.